In breast cancer, the expression of PR is frequently assessed along with estrogen receptor (ER) status to classify the cancer and guide treatment. PR-positive breast cancers are often more responsive to hormone therapies, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors, which aim to block hormone signaling pathways that promote tumor growth.
